Posted 1 hour ago,
Reading 2 mins.
The Food and Drug Administration (FDA) has approved a new topical cream to fight plaque psoriasis, an inflammatory skin disease.
The US Food and Drug Administration (FDA) has given the green light to a new treatment for plaque psoriasis, the most common form of the disease.
A once-daily, steroid-free topical cream
About 2.5 million people in France have psoriasis, a chronic inflammatory skin disease that manifests as scaly red patches.
Good news: these skin lesions can be reduced with a new treatment. It is a steroid-free topical cream recently approved by US authorities.
“As a dermatologist, I always welcome any new treatment options for my patients with plaque psoriasis. Tapinarof 1% cream is the latest breakthrough – a first class drug that is completely different from what is currently on the market“, said in the columns of HealthLine Dr. Brian Toy, dermatologist at Providence Mission Hospital.
During the three clinical trials (phase 3), 1000 adults aged 18 to 75 were tested for twelve weeks. A first group used Tapinarof 1% cream; and the other a placebo. The primary endpoint was the global assessment score delivered by a physician.
After 12 weeks, 36% of participants in Trial 1 and 40% of those in Trial 2 achieved the primary endpoint, compared with 6% in the placebo group.
People who used the cream also showed significant improvement in all secondary endpoints, including a 75% or more improvement in their psoriasis.
At the end of the study, 86% of the participants felt that they could more easily treat the disease with this new drug, 84% were satisfied with the results and around 82% said that Tapinarof was more effective than previous treatments. topicals used.
Consult a dermatologist online
Few side effects to report
The side effects of the cream also seem quite limited: folliculitis (hair follicle infection) and/or an acne-like rash.
Finally, Tapinarof cream has the advantage of being topical (the active ingredient does not enter the circulatory system) and it can be used in certain areas of the body where steroid drugs should be avoided: face, skin folds, neck, genitals, anal crux, inflammatory areas, armpits…
“The efficacy of this new drug looks promising“, concludes Dr. Brian Toy.